-
Finance And Funding: Anticipating Improvement, Planning For Uncertainty12/1/2023
Executives responding to this year’s finance and funding outlook questions are optimistic about the potential for a turnaround in 2024.
-
Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place12/1/2023
Biopharmaceutical companies can’t afford to halt production lines due to manufacturing violations next year. Manufacturing and supply chain processes will require fresh thinking and flexibility in 2024.
-
Krystal Biotech’s Side Business: Gene-Based Aesthetics11/1/2023
Krystal Biotech's side business is an aesthetics company, Jeune Aesthetics, that uses the same platform and viral vector as Krystal to deliver collagen genes to consumers seeking aesthetic improvement.
-
The Power Couple Behind Krystal Biotech11/1/2023
Krish and Krishnan, the husband-and-wife team that founded and leads Krystal Biotech, cleared a path to market for the first ever topical and redosable gene therapy.
-
Building A Business Model For Novel Antibiotics11/1/2023
In the challenging development space for novel antibiotics, Spero Therapeutics is using partnership, external validation, and formulation science to develop drugs treating bacterial infections both rare and common.
-
A Family Affair11/1/2023
For Krish and Suma Krishnan, the husband-and-wife leadership team at Krystal Biotech, bringing work home, and bringing home to work, is inevitable. A larger shared goal smooths the edges.
-
Too Much Talk About Technology10/2/2023
To adopt and use new technology effectively, leaders should focus on people and their problems, not the technology itself, according to former Google executive turned biotech CEO.
-
Using AI To Find And Develop Safer Medicines10/2/2023
Montai Health CEO Margo Georgiadis is using what she’s learned at McKinsey, Discover, Google, Mattel, and Ancestry to reinvent drug discovery and development, with a focus on long-term safety.
-
Life Biosciences Grows Up: A Q&A With Jerry McLaughlin10/2/2023
Through the boom and bust of anti-aging buzz cycles, Life Biosciences has continued its focus on epigenetic reprogramming with an increasingly focused pipeline and development strategy.